RVPH
Reviva Pharmaceuticals Holdings, Inc.NASDAQHealthcare$0.71-1.11%ClosedMarket Cap: $2.4M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
0.69
DCF Value
$3,070,093.41
FCF Yield
-1013254817.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-918.9%
ROA
-124.8%
ROIC
-223.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-20.20T | $-19.86T | $-5.21 | — |
| FY 2025 | $0.00 | NaN% | $-20.20T | $-19.86T | $-5.48 | — |
| Q3 2025 | $0.00 | NaN% | $-4.0M | $-4.0M | $-1.10 | — |
| Q2 2025 | $0.00 | NaN% | $-6.1M | $-6.1M | $-2.40 | — |
| Q1 2025 | $0.00 | NaN% | $-6.5M | $-6.4M | $-2.60 | — |
| Q4 2024 | $0.00 | NaN% | $-6.3M | $-6.3M | $-3.20 | — |
| FY 2024 | $0.00 | NaN% | $-30.8M | $-29.9M | $-18.00 | — |
| Q3 2024 | $0.00 | NaN% | $-8.5M | $-8.4M | $-5.00 | — |
| Q2 2024 | $0.00 | NaN% | $-8.1M | $-7.9M | $-5.20 | — |
| Q1 2024 | $0.00 | NaN% | $-7.9M | $-7.4M | $-5.00 | — |
| Q4 2023 | $0.00 | NaN% | $-10.0M | $-9.7M | $-7.20 | — |
| FY 2023 | $0.00 | NaN% | $-39.5M | $-39.3M | $-33.00 | — |